Bridging the Gap Between Effective Therapies and Optimal Clinical Outcomes - 24/02/24
Doi : 10.1016/j.amjmed.2023.11.012
Ralph Snyderman, MD a, b, ⁎ 
, Kathy Z. Dai, MD a, b, Christopher M. O'Connor, MD, MACC b, c
, Kathy Z. Dai, MD a, b, Christopher M. O'Connor, MD, MACC b, c a Duke Center for Personalized Health Care, Durham, NC
b Duke University School of Medicine, Durham, NC
c Inova Heart and Vascular Institute, Falls Church, VA
⁎Requests for reprints should be addressed to Ralph Snyderman, MD, Duke University, DUMC 3059, Durham, NC 27710.Duke UniversityDUMC 3059DurhamNC27710
Le texte complet de cet article est disponible en PDF.
Plan
| Funding: None. |
|
| Conflicts of Interest: RS serves on the board of directors of iRhythm Technologies, DNAnexus, Heartland Whole Health Institute, and ZealCare, where he is also a co-founder, and OrthoTheapeutics, Inc. Scientific Advisory Board. CMO serves on the board of directors and is a consultant of ZealCare, as well as an advisor to Merck, Renovacor, and Abiomed. KZD reports no conflicts of interest. |
|
| Authorship: All authors had access to data and participated in the preparation of this manuscript. |
© 2023
Elsevier Inc. Tous droits réservés.
Vol 137 - N° 3
P. 192-194 - mars 2024 Retour au numéro
Article précédent
- New Clinical Challenges for Health Providers in the Prescription of Statins in the Elderly
- Charles H. Hennekens, Akshay Suvas Desai, Rishiraj Bandi, Shalakha Bonthu, Marc A. Pfeffer, Allison H. Ferris
- Why Tests Alone Are Inherently Insufficient
- Ami Schattner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?